Information for health care professionals
The UK-labelled ERWINASE product is from the global batch and is the same as the Canadian product with respect to composition.
The following differences between the currently approved Canadian and UK labelling should be noted:
Table 1 - ERWINASE VIAL LABEL
|
Section of the label |
UK |
Canada |
|
Name of Product |
Erwinase® 10,000 Units Lyophilisate for solution for injection
10,000 Units /vial |
Erwinase® 10 000 U.
Sterile freeze-dried powder |
|
Crisantaspase (asparaginase from Erwinia chrysanthemi, Erwinia L-asparaginase) |
Erwinia L-asparaginase |
|
Reconstitution |
Reconstitute before use. |
Dissolve in 1 or 2 mL of Sodium chloride Injection, USP. |
|
Marketing Authorization Holder |
Porton Biopharma Limited
Porton Down
Salisbury, SP4 0JG |
EUSA Pharma SAS |
|
Excipients |
Sodium Chloride,
Glucose Monohydrate |
Not reported on the vial label |
|
Distributor/Local Representative |
EUSA Pharma (Europe) Ltd. |
CGF Pharmatech Inc.
Montreal Canada |
|
MA number |
PL44403/002 |
DIN 02237815 |
|
Others |
No other information on vial label |
Refer to the enclosed information leaflet |
Table 2 - BOX LABEL
|
Section |
UK |
Canada |
|
All |
English only |
French Translation |
|
Name of Product |
Erwinase® 10,000 Units Lyophilisate for solution for injection |
Erwinase® 10 000 U.
Sterile freeze-dried powder Antileukemic |
|
Crisantaspase (asparaginase from Erwinia chrysanthemi, Erwinia L-asparaginase) |
Erwinia L-asparaginase for injection |
|
|
Each vial contains:
10,000 Units crisantaspase |
Each vial contains: Erwinia
L-asparaginase 10,000 Units |
|
Marketing Authorization Holder (MAH) |
Porton Biopharma Limited
Porton Down
Salisbury, SP4 0JG |
EUSA Pharma SAS
Limonest, France, 69760 |
|
Excipients |
Sodium Chloride,
Glucose Monohydrate |
Glucose 5.0 mg;
Sodium chloride 0.5 mg |
|
Reconstitution |
Reconstitute before use. |
Dissolve in 1 or 2 mL of Sodium chloride Injection USP.
Gently agitate to dissolve. Use only if clear. |
|
Distributor/Local Representative |
EUSA Pharma (Europe) Ltd |
CGF Pharmatech Inc. Montreal Quebec, H4T 1A7 |
|
MA number |
PL44403/002 |
DIN 02237815 |
|
Others |
|
Contains no preservative.
For dosage and directions for use see package insert. |
For complete prescribing information, including Dosage and Administration, please refer to the ERWINASE Canadian Product Monograph.
Vials of ERWINASE with visible particulate matter must not be administered. Please notify and retain the vial for collection.
Similarly to the Canadian product, the contents of each vial of UK-labelled ERWINASE should be reconstituted in 1 to 2 mL of sodium chloride (0.9%) solution for injection. Slowly add the reconstitution solution against the inner vial wall, do not squirt directly onto or into the powder. Allow the contents to dissolve by gentle mixing or swirling maintaining the vial in an upright position. Avoid froth formation due to excessive or vigorous shaking.
The solution should be clear without any visible particles. Fine crystalline or thread-like wisps of protein aggregates may be visible if shaking is excessive. If there are any visible particles or protein aggregates present, the reconstituted solution should not be used and the vial and content should be discarded.
Even if there is no visible particulate matter after reconstitution, in order to minimise the potential risk of exposure to sub-visible particulate matter, use
a standard 5 micron filter needle to withdraw the reconstituted product from the vial prior to administration as an additional precaution. A study has demonstrated that filtration through a 5 micron filter needle after reconstitution has no effect on ERWINASE activity.
The solution should be administered within 15 minutes of reconstitution. If a delay of more than 15 minutes between reconstitution and administration is unavoidable, the solution should be withdrawn into a glass or polypropylene syringe for the period of the delay. The solution should be used within 8 hours.
In the event that you discover particulate matter, pre- or post- reconstitution, please notify the Customer Services department and retain the vial for collection.
Action taken by Health Canada
In light of a potential shortage, Health Canada, per the conditions agreed upon by Jazz Pharmaceuticals, has not objected to the importation of UK-labelled ERWINASE BATCH 180G. Health Canada will continue to monitor the situation.